We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Generics Lose as Court Protects Pfizer’s Lyrica Through 2018
Generics Lose as Court Protects Pfizer’s Lyrica Through 2018
July 31, 2012
Pfizer is trumpeting its exclusive rights to one of its best-selling products until late 2018 after a Delaware district court upheld its patents on pain and seizure drug Lyrica.